Search

everythinglearnresearchcommunity

for

Search:↓

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

Kalya Research is an AI tool that effectively finds and analyzes alternative medicine literature, saving researchers time.

The workshop promoted better medicine use and health practices through global collaboration.

The workshop successfully promoted better medicine use and international collaboration.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Promising cancer treatments were found, but the manufacturer closed.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

The congress showed that psychological therapy can help skin condition patients, social media affects acne stigma, education improves atopic dermatitis, and patient satisfaction in dermatology is high, especially with good doctor engagement.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Pexidartinib often causes liver issues and fatigue, especially in women.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.